Swiss pharmaceutical company Roche has announced that a new antibiotic, zosurabalpin, is progressing to phase 3 testing.

Roche (RHHBY) is planning to move a new antibiotic into late stage clinical trials after early studies showed it had ...

The Swiss drugmaker says the safety and efficacy of zosurabalpin will be investigated in a study involving 400 patients with ...

Roche is planning to move a new antibiotic into late-stage clinical trials after studies showed it had potential to tackle a ...

Swiss drugmaker Roche said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that ...

New ‘superbug’ antibiotic to treat sepsis and pneumonia enters last phase of testing - It is hoped that the drug zosurabalpin ...

Roche is moving its novel antibiotic zosurabalpin into phase 3 testing for carbapenem-resistant Acinetobacter baumannii (CRAB), a 'superbug' that is considered an 'urgent threat' by the CDC, in what ...

Roche has shared long-term phase 2 data on its BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS), | Roche has ...

Roche has revealed new results from a phase 2 trial of its oral BTK inhibitor fenebrutinib in relapsing multiple sclerosis (MS) that suggest it can prevent progression of the disease for nearly two ...

A group of advisers to the Food and Drug Administration said Roche Holding AG needs to study its blood cancer treatment in ...

FRANKFURT — Swiss drugmaker Roche (ROG.S), said on Monday it would advance testing of an antibiotic against a common drug-resistant bacteria that causes serious hospital infections into the ...